Article
Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.
Critical reviews in oncogenesis - 1 Jan 2022
Hofstad Mia, Huang Emily Y, Woods Andrea, Yin Yi, Desai Neil B, Raj Ganesh V
Abstract excerpt
Prostate cancer (PCa) is one of the leading causes of cancer diagnoses and cancer-related deaths in the United States. Mutations or deletions in the genes involved in the DNA damage response (DDR) are common in aggressive primary PCa (germline alterations) and further enriched in advanced therapy-resistant PCa (somatic alterations). Among the DDR genes, BRCA2 is the most commonly altered (~ 13%) in advanced...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.